Vitiligo induced by secukinumab
10.3760/cma.j.cn114015-20231220-00918
- VernacularTitle:司库奇尤单抗诱发白癜风
- Author:
Yang CHEN
1
;
Kezhou ZHANG
;
Qi ZHU
;
Jun WANG
Author Information
1. 中国人民解放军海军第九七一医院皮肤病科，青岛 266071
- Publication Type:Journal Article
- Keywords:
Psoriasis;
Vitiligo;
Secukinumab;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2024;26(7):442-443
- CountryChina
- Language:Chinese
-
Abstract:
A 37-year-old male patient with plaque psoriasis received treatment with secukinumab (injection of secukinumab 300 mg at weeks 0, 1, 2, 3, and 4, once per week, followed by 1 dose/4 weeks). After 3 months of treatment, the psoriasis rash completely subsided, but the patient had depigmented patches of varying sizes on the dark brown pigment imprints on the lower back, and hands, with an area did not exceeding the original pigment imprint range. Under the Wood lamp, the lesions appeared as clearly defined and bright blue white patches, diagnosed as vitiligo. It was considered that vitiligo possibly was caused by secukinumab. The patient had no pain, itching or other symptoms in the lesions and was not treated. After 2 months of continued treatment with secukinumab, no significant changes were observed in the white patches.
